LGND News and Press, Ligand Pharmaceuticals Incorporated From 01/26/21

When opportunities surface Wall Street pays attention.  Investors are greedy, and when they see an opportunity to make money investors not only try to maximize their results but they try to replicate the opportunity as much as possible too.  Recently, that opportunity has been to ...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided today details of its plans to report fourth quarter 2020 financial results on February 3, 2021. Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg will host th...

Triggered by the U.S. Food and Drug Administration acceptance for review of a biologics license application for V114, Ligand Pharmaceuticals (LGND) received a $1.5M milestone payment from Merck.V114 is an investigational 15-valent pneumococcal conjugate vaccine candidate for th...

Milestone payment triggered by acceptance for review of a BLA for V114, an investigational 15-valent pneumococcal conjugate vaccine that utilizes Ligand’s CRM197 carrier protein Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported that the company will re...

Virgin Galactic Holdings Inc. (SPCE), National Beverage Corp. (FIZZ), Ligand Pharmaceuticals Incorporated (LGND), and AMC Entertainment Holdings, Inc. (AMC) have seen significant shorting activity by investors this year, which is an indication of potential trouble ahead for these stocks. Natu...

Ligand Pharmaceuticals's ([[LGND]] +0.04%) unit Icagen and GlaxoSmithKline ([[GSK]] -2.3%) have entered into a collaboration and license agreement that will utilize Icagen discovery technology to identify and develop inhibitors of a specific genetically-validated molecular target relevant to ...

Ligand Group is eligible to receive an upfront payment of $7 million and potential milestone payments and fees of up to $154.5 million and tiered royalties Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today a collaboration and license agreement between it...

AbCellera Biologics has filed to raise $357 million in an IPO. The firm provides an antibody research platform to biopharmaceutical firms worldwide. ABCL has grown from a small base but the IPO appears highly priced, so I'll pass on it. For further details see: AbCellera...

Ligand has an interesting business plan that it is executing well. Ligand has three technologies that it calls out as important for its near- to mid-term success. CAPTISOL is at the center of Ligand's current revenue-generating business operations. The company's growth prospec...

Two large pharma partners reach clinical-development milestones with OmniAb-derived antibody programs and Ligand earns $4.5 million in milestone payments CStone Pharmaceuticals announces China NDA submission and data for its OmniAb-derived antibody to treat non-small cell lung...